US UDI deadlines near but medtech still none the wiser on exception criteria
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has released information on how medical device labelers may request for an exception from, alternative to or more time to meet the impending requirements on unique device identification (UDI)1,2. However, the information fails to explain the criteria the agency will use to assess requests from companies as they work to meet the UDI compliance deadline, which starts to kick in on 24 September.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.